Dennis L. Spangler, MD Inr!"u#i!n Asthma affects approximately 23 million American children and adults, resulting in almost 15 million physician office and hospital visits, and nearly 2 million emergency department visits each year. Despite the publication of National Asthma ducation and !revention !rogram guidelines, asthma remains poorly controlled, "ith annual costs estimated at up to #5$ billion. %urrent guidelines recommend long&term treatment "ith inhaled corticosteroids '(%)* because of their superior effectiveness in managing the chronic air"ay inflammation that characteri+es persistent asthma. (%) monotherapy should be explored before alternatives such as leu,otriene modifiers and long&acting beta agonists '-A.As* are attempted, especially after the /) 0ood and Drug Administrations 2111 "arning that -A.As should never be used alone to treat asthma due to the increased ris, of severe exacerbations leading to hospitali+ation in both children and adults, "ith a possibility of death. (n the past, asthma treatment focused solely on the central air"ays, rather than the small, more distant air"ays, and most traditional (%) therapies are aerosols "hich deliver large particles to the central air"ays. 2oday, the importance of the role of small air"ay disease in asthma, particularly inflammation, is ,no"n. 2argeting the small air"ays may help improve clinical outcomes and reduce healthcare utili+ation and costs. 2he (%) beclomethasone dipropionate 30A does not re4uire a spacer and is characteri+ed by small particle si+es that result in more of the drug being deposited in both the large and small air"ays. )tudies have demonstrated that beclomethasone dipropionate 30A is clinically effective and cost efficient compared "ith other asthma monotherapies or combination therapies. ASTHMA Asthma affects approximately 23 million Americans, including almost 5 million children 'as of 2116*, and it is estimated that by 2125 that number "ill gro" by more than 111 million "orld"ide. Asthma is responsible for almost 15 million physician office and hospital visits, and nearly 2 million visits to emergency departments, every year. (n addition, results from the survey Asthma in America indicate that the /nited )tates is not meeting asthma goals set forth by the National 3eart, -ung, and .lood (nstitute, "hich consist of no sleep disruption, no missed school or "or,, no 'or minimal* need for emergency department visits7hospitali+ations, maintenance of normal activity levels, and normal or near& normal lung function. 2his lac, of control has contributed to the annual economic costs associated "ith asthma, "hich have been estimated to be as high as #5$ billion. %urrent guidelines recommend long&term treatment "ith inhaled corticosteroids '(%)* because of their superior effectiveness in managing the chronic air"ay inflammation that characteri+es persistent asthma. Additionally, the /) 0ood and Drug Administration '0DA* issued a "arning in 0ebruary 2111 that long&acting beta agonists '-A.As* should never be used alone to treat asthma, specifying that "hen they are used, they should be administered only for the shortest duration possible and then discontinued. 2his "arning resulted from analyses sho"ing that -A.A use "as associated "ith an increased ris, of severe exacerbations leading to hospitali+ation in both children and adults, "ith a possibility of death. 2he National Asthma ducation and !revention !rogram 'NA!!* xpert !anel 8eport '!8*&3 9uidelines recommend a step"ise approach to asthma treatment. (%) monotherapy as first&line controller treatment for persistent asthma 'mild, moderate, and severe* for both adults and children.(f asthma remains uncontrolled "ith lo"&dose (%) monotherapy, only then should physicians consider a medium& dose (%) or adding a -A.A to a lo"&dose (%) regimen.(ncreasing the (%) dose may reduce the ris, of severe exacerbations and hospitali+ations compared "ith approaches that involve adding a -A.A.11 A study of more than $:,111 patients found treatment to be more successful among those "ho "ere given stepped up (%) monotherapy compared "ith patients given (%)7-A.A combination treatment 'odds ratio ;<8= 1.55 vs 1.>$*. !atients given (%) only "ere 31? less li,ely to be hospitali+ed for respiratory issues than those receiving (%)7-A.A treatment.112he National (nstitute for 3ealth and %linical xcellence 'N(%*, "hich is based in the /nited @ingdom, recommends (%) treatment as step 2 '"ith a short&acting beta agonist ;)A.A= as step 1 for mild intermittent asthma* if the patient meets the follo"ing re4uirementsA %ontinued asthma exacerbations "ithin the past 2 years. 2he patient is using a )A.A at least 3 times per "ee,. 2his does not include use for exercise&induced asthma. 2he patient has symptoms at least 3 times per "ee,. 2he patient "a,es at night due to symptoms Despite these recommendations ho"ever, the use of (%) monotherapy has been sho"n to be suboptimal. Although -A.A7(%) therapy is not recommended as first&line treatment, and (%) therapy is less costly than -A.A7(%) treatment or leu,otriene modifiers, evidence indicates physicians are still predominately prescribing -A.A7(%) regimens or a leu,otriene modifier rather than attempting to utili+e the full potential of (%) monotherapy. (n the past, asthma treatment tended to focus solely on the central air"ays, rather than the small, more distant air"ays 'air"ay diameter 2 mm*. 2oday, the importance of the role of small air"ay disease in asthma, particularly inflammation, is no" ,no"n. (nitially thought to be the 4uiet +one of the lungs, contributing little to total lung resistance, more recent technology such as fiber optic bronchoscopy has given "ay to an understanding that the small air"ays contribute significantly to air"ay resistance. Among patients "ith mild asthma having normal spirometry, small air"ay resistance "as increased up to 5& fold "hen compared "ith controls. !atients "ith asthma "ho are asymptomatic can also sho" significant increases in small air"ay resistance, in most cases caused by poorly treated distal lung inflammation. 2he inflammatory process in the central and distal air"ays is similar 'infiltrates contain activated 2 lymphocytes and eosinophils, increased mucus plugging, and smooth muscle hyperplasia*, "ith one important difference. 2he small air"ays are a maBor site of air"ay obstruction because of their small diameter, and because smaller amounts of inflammation result in a greater degree of air"ay narro"ing and may contribute significantly to air"ay hyperresponsiveness. 8emodeling can also occur in the small air"ays of patients "ith asthma. A study sho"ed that among patients "ith asthma "ho had died, most "ere ta,ing large&particle (%). Autopsy data indicated that air"ay remodeling "as not altered by large&particle (%) therapy. 2hese structural changes that occur amid air"ay hyperresponsiveness may result from long&standing or undertreated air"ay inflammation. 2he use of small&particle (%) has been sho"n to reduce small air"ay inflammation. 2argeting the small air"ays can help improve clinical outcomes, reduce healthcare utili+ation7costs, and improve 4uality of life. Diagnosing small air"ay dysfunction and treating the patient early may reverse air"ay remodeling, progression to air"ay fibrosis, and irreversible air"ay damage in patients "ith mild&to&moderate asthma. Although (%) treatment is the gold standard for treating asthma, aerosol particle si+e is crucial, "ith only small, less dense particle si+es having the ability to reach the small air"ays. !articles bet"een 1.$ and 1.3 mm are li,ely to be exhaled, and therefore of less therapeutic benefit. Although delivery method and dosage vary bet"een (%) products, most traditional (%) therapies are aerosols that deliver large particle si+es '2.: to :.5 mm* to the central air"ays, resulting in relatively lo" total lung deposition. -arge&particle metered&dose inhalers, pressuri+ed inhalers, or dry&po"der inhalers have not sho"n great efficiency, delivering drug to the smaller air"ays at no more than 31? of the administered dose. 2he ,ey treatment for asthma are steroids and other anti&inflammatory drugs. 2hese asthma drugs both help to control asthma and prevent asthma attac,s. )teroids and other anti&inflammatory drugs "or, by reducing inflammation, s"elling, and mucus production in the air"ays of a person "ith asthma. As a result, the air"ays are less inflamed and less li,ely to react toasthma triggers, allo"ing people "ith symptoms of asthma to have better control over their condition. Signs !$ a %en"ing As&'a Aa#( a. Chat Are the Dain 2ypes of )teroids and Anti&(nflammatory Drugs for AsthmaE 2he main types of anti&inflammatory drugs for better asthma control are steroids or corticosteroids. <ther anti&inflammatory treatments include mast cell stabili+ers, leu,otriene modifiers, and immunomodulators. b. Chat Are (nhaled )teroidsE (nhaled steroids are the mainstay treatment for controlling asthma. 2he use of inhaled steroids leads to better asthma control 0e"er symptoms and flare&ups 8educed need for hospitali+ation Note that "hile inhaled steroids help prevent asthma symptoms, they do not relieve asthma symptoms during and attac,. Dosages of inhaled steroids in asthma inhalers vary. 2he ,ey treatment for asthma are steroids and other anti&inflammatory drugs. T&ese as&'a "rugs )!& &elp ! #!nr!l as&'a an" pre*en as&'a aa#(s. )teroids and other anti&inflammatory drugs "or, by reducing inflammation, s"elling, and mucus production in the air"ays of a person "ith asthma. As a result, the air"ays are less inflamed and less li,ely to react toasthma triggers, allo"ing people "ith symptoms of asthma to have better control over their condition. Note that "hile inhaled steroids help prevent asthma symptoms, they do not relieve asthma symptoms during and attac,. Dosages of inhaled steroids in asthma inhalers vary. (nhaled steroids need to be ta,en daily for best results. )ome improvement in asthma symptoms can be seen in one to three "ee,s after starting inhaled steroids, "ith the best results seen after three months of daily use. In&ale" ser!i" 'e"i#ai!ns $!r )eer as&'a #!nr!l in#lu"e + a. Advair 'a combination drug that includes a steroid and a long & acting bronchodilator drug*. b. Aerobid Asmanex A+macort Dulera 'a combination drug that also includes a long&acting bronchodilator drug*. c. 0lovent !ulmicor t)ymbicort 'a combination drug that includes a steroid and a long&acting bronchodilator drug*. (nhaled steroids come in three forms the metered dose inhaler 'DD(*, dry po"der inhaler 'D!(*, and nebuli+er solutions. ,&a Are &e Si"e E$$e#s !$ In&ale" Ser!i"s- (nhaled steroids have fe" side effects, especially at lo"er doses. (f you are ta,ing higher doses, thrush 'a yeast infection in the mouth* and hoarseness may occur, although this is rare. 8insing the mouth, gargling after using the asthma inhaler and using a spacer device "ith metered dose inhalers "ill help prevent these side effects. 2hrush is easily treated "ith an antifungal mouth"ash. (nhaled steroids 'asthma inhalers* are safe for adults and children. )ide effects "ith these anti&inflammatory asthma inhalers are minimal. Four doctor "ill prescribe the lo"est dose that effectively controls yours or your childGs asthma. <n a side note, many parents are concerned about giving their children Hsteroids.H 2he inhaled steroids are not the same as anabolic steroids that some athletes ta,e to build muscle. 2hese steroids are anti&inflammatory drugs, the cornerstone of asthma therapy. 2here are many benefits of using anti&inflammatory asthma inhalers to self&manage asthma. 2o learn more about using inhaled steroids in children, see CebDDGs article on %hildhood Asthma. ,&a Are &e .ene$is !$ /sing In&ale" Ser!i"s- 2he benefits of inhaled steroids for better asthma control far exceed their ris,s, and includeA & 8educed fre4uency of asthma attac,sDecreased use of beta&agonist bronchodilators '4uic, relief or rescue inhalers*(mproved lung function8educed emergency room visits and hospitali+ations for life& threatening asthma H!0 D! %re"nis!ne an" Syse'i# Ser!i"s ,!r( ! In#rease As&'a C!nr!l- /sing systemic steroids 'steroids ta,en by mouth or by inBection that can affect the entire body* such as prednisone, prednisolone, and methylprednisolone help to treat severe asthma episodes, allo"ing people to gain better asthma control.!rednisone and other steroid drugs may be used to help control sudden and severe asthma attac,s or in rare cases to treat long&term, hard&to&control asthma. Dost often, prednisone or other steroid is ta,en in high doses for a fe" days 'called a steroid burst* for more a severe asthma attac,. )ide effects of systemic steroids include A a. Cea,ness b. Acne c. Ceight gain d. Dood or behavior changes e. /pset stomach f. .one loss g. ye changes h. )lo"ing of gro"th. 2hese side effects rarely occur "ith short&term use, such as for an acute asthma attac,. 0or in&depth information, see CebDDGs article on !rednisone and Asthma. H!0 D! &e Leu(!riene M!"i$iers I'pr!*e As&'a C!nr!l- Accolate, )ingulair, and Iyflo are called leu,otriene modifiers. -eu,otrienes are inflammatory chemicals that occur naturally in our bodies and cause tightening of air"ay muscles and production of mucus. -eu,otriene modifier drugs help control asthma by bloc,ing the actions of leu,otrienes in the body. )tudies sho" that these medications are helpful in improving airflo" and reducing asthma symptoms. 2he leu,otriene modifiers are ta,en as pills and have been sho"n to decrease the need for other asthma medications. 2hese medications have been sho"n to be effective in people "ith allergic rhinitis'nasal allergies* and may be effective in people "ith both allergic rhinitis and allergic asthma. ,&a Are &e Si"e E$$e#s !$ Leu(!riene M!"i$iers- 2he most common side effects of leu,otriene modifiers are headache, nausea, vomiting, insomnia, and irritability. -eu,otriene modifiers may interfere "ith other medications 'for example, theophylline and the blood thinner "arfarin*. Da,e sure you inform your doctor of all the medications you are ta,ing. ,&a Are &e Mas Cell Sa)ili1ers- Dast cell stabili+ers, such as cromolyn sodium, are inhaled asthma medications 'asthma inhalers* that "or, by preventing the release of inflammatory substances 'histamines* from immune cells called mast cells. 2hey help prevent and reduce asthma symptoms, especially in children "ithallergies and asthma and in people "ith exercise&induced asthma. 2hese asthma inhalers need to be ta,en t"o to four times a day, and they ta,e three to four "ee,s to start "or,ing. 2hese asthma inhalers have side effects that include dry throat, cough, "hee+ing, throat irritation, and bad taste. H!0 D! I''un!'!"ula!rs ,!r( ! I'pr!*e As&'a C!nr!l- Jolair 'omali+umab*, an immunomodulator, "or,s differently than other anti& inflammatory medications for asthma. Jolair bloc,s the activity of (g 'a protein that is overproduced in people "ith allergies* before it can lead to asthma attac,s. (mmunomodulator treatment has been sho"n to help reduce the number of asthma attac,s in people "ith moderate to severe allergic asthma "hose symptoms are not controlled "ith inhaled steroids Jolair, a prescription medication, is given by inBection every t"o to four "ee,s. (tGs recommended for people "ith moderate to severe allergic asthma. )ide effects include redness, pain, s"elling, bruising or itching at the inBection site, Boint pain, and tiredness. (t may increase ris, for certain cancers and carries a boxed "arning about severe, potentially life&threatening allergic reaction 'anaphylaxis*. httpA77""".aBmc.com7publications7supplement721127A322K12LanKAsthma72he& 8ole&of&(nhaled&%orticosteroids&in&Asthma&2reatment&A&3ealth&conomic& !erspective7Msthash.x/c"r>5F.dpuf